The Impact of Digital Adherence Technologies on Health 1 **Outcomes in Tuberculosis: A Systematic Review and Meta-**2 Analysis 3

4 5

Mona S. Mohamed¹, Miranda Zary¹, Cedric Kafie¹, Chimweta I. Chilala², Shruti 6 Bahukudumbi³, Nicola Foster², Genevieve Gore⁴, Katherine Fielding², Ramnath 7 Subbaraman^{3,5}, Kevin Schwartzman¹ 8

- 9 10
- ¹McGill International Tuberculosis Centre: Research Institute of the McGill University Health 11 Centre, Montréal, Canada 12
- ²TB Centre, London School of Hygiene and Tropical Medicine, London, UK 13
- ³Department of Public Health and Community Medicine, Tufts University School of Medicine, 14 15 Boston, USA
- ⁴Schulich Library of Physical Sciences, Life Sciences, and Engineering; McGill University, 16
- Montréal, Canada 17
- ⁵Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, 18 19 USA
- 20
- 21
- Word count: 22
- 23 Abstract: 403 words
- Full text: 5341 words 24
- 25
- 26
- Key words: Tuberculosis, digital technologies, adherence. 27
- 28

30 31 32 33 34	1	Dr. Kevin Schwartzman Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre 5252 boulevard de Maisonneuve Ouest, Room 3D.63 Montreal, Quebec H4A 3S5 CANADA Email kevin schwartzman@mcgill ca
35		Email kevin.schwartzman@mcgill.ca

- 36
- Funding: This review was supported by a grant from the Bill and Melinda Gates Foundation 37 (grant INV-038215). 38

39

- Competing Interests: Dr. Kevin Schwartzman reports research funding from the Canadian 40
- Institutes of Health Research. He has also served as chair of the Data Safety and Monitoring 41 Board for a COVID-19 therapeutic investigated by Laurent Pharmaceuticals. 42
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract 43

44

Background: Suboptimal tuberculosis (TB) treatment adherence may lead to unsuccessful 45 46 treatment and relapse. Digital adherence technologies (DATs) may allow more person-centric approaches for supporting treatment. We conducted a systematic review (PROSPERO-47 CRD42022313166) to evaluate the impact of DATs on health outcomes in TB. 48

49

Methods: We searched MEDLINE, Embase, CENTRAL, CINAHL, Web of Science and 50 preprints from medRxiv, Europe PMC, and clinicaltrials.gov for relevant literature from 51 January 2000 to April 2023. We considered experimental or cohort studies reporting 52 53 quantitative comparisons of clinical outcomes between a DAT and the standard of care in each 54 setting.

55

Results: Seventy studies (total 58,950 participants) met inclusion criteria. They reported SMS-56 based interventions (k=18 studies), feature phone-based interventions (k=7), medication 57 sleeves with phone calls (branded as "99DOTS," k=5), video-observed therapy (VOT; k=17), 58 59 smartphone-based interventions (k=5), digital pillboxes (k=18), ingestible sensors (k=1), and interventions combining 2 DATs (k=1). Overall, the use of DATs was associated with more 60 frequent treatment success in TB disease (OR = 1.18 [1.06, 1.33]; $I^2 = 66\%$, k = 46), a decrease 61 in loss to follow up (OR = 0.71 [0.53, 0.94]; $I^2 = 80\%$, k = 36) and an increase in adverse event 62 reporting (OR = 1.53 [1.26, 1.86]; $I^2 = 0\%$, k = 9). VOT was associated with an increased 63 likelihood of treatment success in TB disease (OR 1.54 [1.09; 2.19]; $I^2 = 0\%$, k = 8) and 64 treatment completion in TB infection (OR 4.69 [2.08; 10.55]; $I^2 = 0\%$, k = 2) as well as an 65 increased frequency of adverse event reporting (OR = 1.79 [1.27; 2.52]; $I^2 = 34\%$, k = 4). Other 66 interventions involving smartphone technologies were associated with increased treatment 67 success in TB disease (OR 1.98 [1.07; 3.65]; $I^2 = 56\%$, k = 5) and a decreased frequency of loss 68 to follow up (OR = 0.31 [0.13; 0.77]; $I^2 = 36\%$, k = 5). Digital pillboxes were also associated 69 with an improvement in treatment success (OR = 1.32 [1.00; 1.73]; I² = 71%, k = 11). However, 70 71 improved treatment success was only seen in high- and upper middle-income countries. SMSbased interventions, feature-phone interventions and 99DOTS were not associated with 72 improvements in short-term clinical outcomes. 73

74

Conclusion: Certain DATs--notably VOT and smartphone-based interventions, in higher 75 income settings and sometimes combined with other supportive measures-may be associated 76 77 with improvements in treatment success and losses to follow-up, compared to standard care. 78 However, evidence remains highly variable, and generalizability limited. Higher quality data

are needed. 79

Introduction 80

81

Tuberculosis (TB) is currently the second leading infectious cause of death, eclipsed 82 83 only by the COVID-19 pandemic. About one-quarter of the world's population is estimated to have been infected with Mycobacterium tuberculosis.[1] In 2022, an estimated 10.6 million 84 people developed TB disease worldwide, of whom 1.3 million died.[2] 85

86

87 Suboptimal adherence to treatment for TB disease may lead to treatment failure, increased risk of death or relapse. To improve adherence, the World Health Organization in 1994 endorsed 88 89 directly observed therapy (DOT) where health workers, community volunteers or family members observe and record patients taking each dose.[3] Digital adherence technologies 90 (DATs) may facilitate more patient-centric, community rather than facility-based, and less 91 92 intrusive approaches for monitoring TB medication adherence than existing DOT models.[4] Depending on the setting and care model, some studies have suggested that DAT-based 93 treatment may be more effective than standard care in achieving favorable treatment 94 95 outcomes.[5] However, findings regarding health outcomes have been inconsistent and may vary by country income level and technology type. [6-8] 96

97

98 We conducted a systematic review and meta-analysis to evaluate the impact of DATs on health 99 outcomes in persons treated for TB disease and TB infection.

- 100
- 101
- 102

Methods 103

104

Our systematic review and meta-analysis was conducted and reported using the Preferred 105 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[9] (S1 106 checklist), and followed a protocol registered as PROSPERO-CRD42022313166. 107

108

Search Strategy and study selection 109

110

On April 25th, 2023 (updated from April 14th, 2022), we searched MEDLINE(Ovid), Embase 111 (Ovid), CENTRAL (Wiley), CINAHL, Web of Science Core Collection, Europe PMC 112 preprints (including MedRxiv) and ClinicalTrials.gov (for unpublished clinical trials). from 113 January 1st, 2000, to April 14th, 2023. The search was conducted by a health sciences librarian 114 (GG) to ensure that the most suitable search terms were used. Key elements included terms that 115 denoted **tuberculosis** (disease or infection): **digital technologies** and tools (including mobile 116 117 phone, smartphone, video observation, medication monitors, text messaging, etc.) and health outcomes (microbiologic conversion, treatment success, microbiologic cure, treatment failure, 118 119 death, loss to follow-up, relapse/ recurrence, subsequent TB disease after treatment for latent 120 TB infection, medication adherence, and patient-reported outcomes). More detailed information about the search strategy and results is provided in S1 Table. 121

122

123 We also hand-searched conference abstracts from the Union World Conference on Lung Health from 2004 to 2022 and cross-checked reference lists and citations of included studies as a 124 supplementary approach to identify further data sources. 125

126

We followed a PICOS format (participants, interventions, comparator, outcomes, and study 127 design) to formulate the clinical question used for including studies in the systematic review. 128

129

Study design. We included randomized controlled trials (RCTs), quasi-experimental studies, 130 and cohort studies. 131

132

Population. The population of interest were individuals diagnosed and treated for TB disease 133 or infection, including persons at risk of unfavorable outcomes (e.g., those with drug-resistant 134 disease, those living with HIV, children). 135

136

Interventions. We considered studies that addressed DATs intended to monitor and support 137 TB treatment adherence, including medication dosing but also visit attendance and continued 138 follow-up. This included reminding patients to take their medications, facilitating digital 139 observation of pill-taking, compiling patient dosing histories and identifying adherence 140 patterns, which facilitate patient-centric approaches for monitoring TB medication adherence. 141 We included all such interventions whether they engaged persons treated for TB, providers, or 142 both. We excluded studies where the technology was an electronic health record used only to 143 log visit attendance or if the intervention consisted only of non-automated "routine telephone 144 calls" to patients. A detailed definition for eligible DAT interventions was developed before 145 study selection and is provided in S2 Table. 146

147

Comparator. To be eligible for inclusion, studies had to report a comparator arm involving 148 standard care in the same settings. This included various forms of directly observed therapy 149 150 (DOT), self- administered therapy (SAT) or a combination of the two. Approaches to DOT used as the standard of care in different studies varied substantially and could include facility-151 based DOT (where people with TB had to visit clinics or other health facilities for in-person 152 observation of dosing), field-based DOT (where a healthcare provider or other treatment 153 supporter visited people with TB at their home or another location for observation of dosing), 154 or family DOT (where a family member or other local supporter observed dosing). 155

156

Outcomes. We considered short- and long-term clinical outcomes, medication adherence, and 157 patient-reported outcomes. Short-term clinical outcomes were treated as binary (yes/no) and 158 included: treatment success, treatment completion, cure, loss to follow up, treatment failure, 159 death during treatment, adverse events, emergence of anti-tuberculous drug resistance, 160 microbiological conversion of sputum smear, completion of intensive phase treatment and 161 composite outcomes of favorable or unfavorable outcomes. Short-term clinical outcomes are 162 defined in S3 Table. 163

164

Long-term clinical outcomes were also treated as binary, and included recurrence or relapse 165 (TB disease), defined as a repeat diagnosis of TB disease within 2 years of successful treatment; 166 post-treatment death, defined as death within 2 years of successful treatment for TB disease; 167 and subsequent risk of TB disease, defined as development of TB disease within 5 years of 168 treatment for TB infection. 169

170

medRxiv preprint doi: https://doi.org/10.1101/2024.01.31.24302115; this version posted February 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Adherence was considered as a binary, ordinal, or continuous outcome depending on the 171 measures used in specific studies: These included indirect measures of medication adherence 172 such as pharmacy refill visits; or more direct measures of medication ingestion as indicated by 173 persons with TB themselves, DAT and DOT records, or biologic testing (e.g. drug metabolites 174 in urine). Patient-reported outcomes were based on suitably validated instruments, 175 administered to persons using or not using DATs, at comparable time points during/after 176 treatment. They included: health-related quality of life (HRQoL), functional status, perceived 177 stigma and satisfaction. 178

179

To be included, studies had to report quantitative comparisons of clinical outcomes between a 180 DAT and standard care with at least 20 participants using the DAT. Clinical outcomes could 181 include treatment outcomes, other health outcomes and/or patient reported outcomes. We 182 included data from full-text publications, preprints, or abstracts without any language 183 184 restriction. We excluded review articles and studies that reported purely qualitative 185 information.

186

After deduplication of items initially retrieved from our search, all remaining items were 187 imported into Rayyan software (Rayyan, Cambridge USA). Selection of studies involved two 188 levels of screening conducted in parallel by two independent reviewers (among MM, MZ, CK, 189 CC, SB, NF). In the first-level screen, all titles and abstracts were screened: all studies 190 addressing TB and DATs were included. A third reviewer (KS, KF, or RS) resolved conflicts. 191 In the second-level screen, two independent reviewers (MM, MZ, CK, SB and NF) screened 192 the full text of studies retained from the title and abstract review. Articles were excluded if they 193 194 did not meet the inclusion criteria. In the event of discordant judgment regarding suitability, a third reviewer (KS) resolved conflicts. Excluded full-texts were stored and the reasons for their 195 exclusion were documented. 196

- 197
- 198 Data Extraction

199

Data extraction was conducted independently by two reviewers (among MM, MZ, CK, CC) 200 into a standardised template. Disagreements between reviewers were resolved by consensus 201 and discussion with a third reviewer (KS) when needed. Data extracted included study 202 characteristics (design, year of study, country, setting, sample size, inclusion and exclusion 203 criteria, limitations, strengths and conclusion), population characteristics (age, sex, number of 204 participants in each group, TB condition, drug resistance, HIV co-infection), DAT intervention 205 206 and comparator (type, duration, frequency of the intervention, approach if suboptimal adherence was detected), and outcomes (number of events in each group, measures of effect 207 (means ratios, risk ratios, or odds ratios with respective confidence intervals). 208

- 209
- 210 **Quality Assessment**

211

Each eligible study was evaluated by two reviewers (MM, MZ, CK, CC) independently to 212 213 assess methodological quality. We judged trials to be either at a low, high, or unclear risk of bias in seven categories using Cochrane's Assessment of Risk of Bias. (S4 Table) 214

- 215
- Similarly, two reviewers independently evaluated each cohort study using the Newcastle 216
- Ottawa Scale. (S5 Table) Disagreements were resolved through discussion between the two 217
- reviewers, and with a third reviewer (KS) when needed. 218

219

Data Synthesis 220

221

For each included study, data were summarized in tabular format to highlight study and 222 participant characteristics, as well as key features of the DAT and comparator interventions 223 224 reported. Results for short-term clinical outcomes were pooled and summarized quantitatively. When treatment success (which includes both successful completion and microbiologic cure) 225 and treatment completion were reported in the same study, we focused on treatment success 226 227 for purposes of meta-analysis. When only treatment completion was reported in a study, we used those data when pooling the results for treatment success. 228

229

Results were pooled using an inverse-variance weighted random effects model to estimate 230 overall odds ratios and 95% confidence intervals. For short-term clinical outcomes, the odds 231 ratio in individual studies was calculated from the number of events in the intervention and 232 control groups. When the direct estimate required for the analysis – an odds ratio with its 95% 233 234 confidence intervals- was provided by the authors, it was used when pooling the data. Risk ratios in individual studies were used when odds ratios were not reported. The reciprocal of 235 odds ratio for unfavorable outcomes was used to calculate the odds ratio for treatment success 236 237 in studies that addressed unfavorable outcomes only, and did not report treatment success. For cluster-randomized trials and stepped-wedge trials we used the direct estimate from analyses 238 that properly accounted for the cluster design. When an effect measure was not reported, 239 available crude data were used to estimate odds ratios and 95% confidence intervals. 240

241

242 Between-study variance was estimated by the DerSimonian-Laird method [10]. The metaanalysis was conduced using R version 4.2.3, R Foundation for Statistical Computing, Vienna, 243 Austria, using the *metafor*[11] and *meta*[12] packages. When substantial heterogeneity was 244 present ($I^2 > 50\%$) we conducted subgroup analyses to explore potential sources. 245

246

Pre-specified subgroup analyses considered the specific DAT interventions as well as income 247 levels in the countries where studies were conducted. Country income level was classified as 248

high, upper-middle, lower-middle or low according to the classification of the World 249 Bank.[13] When the number of pooled studies exceeded 10, publication bias was assessed

250 qualitatively by visual inspection of funnel plot symmetry and quantitatively using Egger's 251

linear regression.[14] A sensitivity analysis was completed with and without data extracted 252

from conference abstracts to confirm the robustness of the results. 253

254

Treatment adherence was summarized in tabular form and described narratively. Odds ratios 255 for adherence results with sufficiently homogeneous assessment measures were presented in 256 forest plots without pooling. When adherence was reported in binary terms, odds ratios or risk 257 ratios provided by the authors were used, or the odds ratio was estimated from the number of 258 events in the intervention and comparison groups. For continuous adherence measurements, 259 the standardized mean difference was calculated and transformed to the log odds using the 260 Hasselblad and Hedges method.[15] As reports were much sparser, results for long-term 261 clinical outcomes, and patient reported outcomes were summarized in tabular form and/ or 262 described narratively following PRISMA guidelines for best practices. 263

264

Grading of evidence 265

266

Finally, we rated the quality of evidence for each outcome we meta-analyzed, based on the 267 268 Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach

which considers study limitations, inconsistency of results, indirectness of evidence, 269 imprecision, and publication bias. 270

271

272

Results 273

274

Our search yielded 9,964 records as shown in Figure 1. After removing 2,580 duplicate records, 275 276 a further 6,698 items were excluded after title and abstract review, as they did not address TB and/or DATs; 683 full texts were therefore retained for further eligibility screening, of which 277 56 studies met inclusion criteria. Our search of the Union Conference abstracts identified 13 278 279 additional studies, and one further study was identified after reviewing citations of all included studies, for a total of 70 included studies. These 70 studies reported on 67 unique study 280 cohorts.[16–18] 281

- 282
- Characteristics of the included studies 283
- 284

Of the 70 included studies, 38 were randomized controlled trials (RCTs) (including one cross-285 over trial), five were quasi-experimental studies, and 27 were cohort studies. In those studies, 286 a total of 29,228 participants used DATs while 29,722 others received standard care. Reports 287 addressed eight types of DAT intervention: SMS-based interventions (k=18), feature phone-288 based interventions (k=7), medication sleeves with phone calls (hereafter referred to by its 289 290 brand name "99DOTS" (k=5), video-observed therapy VOT (synchronous and/or asynchronous) (k=17), other interventions based on smartphone technology (k=5), digital 291 pillboxes (medication event reminder monitor (MERM)) (k=18), ingestible sensors (k=1) and 292 293 interventions involving a combination of DATs (k=1).

294

VOT and ingestible sensors were exclusively used in high income countries (HICs) and upper-295 296 middle income countries (UMICs), while DATs used in low-income countries (LICs) included SMS, feature phone-based interventions, digital pillboxes and 99DOTS. 297

298

299 Of the 70 included studies, 9 used facility-based DOT as the comparator, three gave the patients the choice between facility- or field-based DOT, 9 used field-based DOT provided by a health 300 worker, of which three allowed observation at home, two used DOT provided by a family 301 302 member or friend, 15 used DOT but did not provide further details, 9 used self-administered treatment, 8 used a combination, and 15 were unclear.(S6 Table) 303

304

Among participants in the included studies, 99DOTS was provided to the largest number 305 306 (42.5%). A summary of study and participant characteristics is provided in Table 1, while Fig. 2 highlights DATs reported according to country and income level. Detailed characteristics of 307 each study, participants, interventions used, and outcomes reported are listed in (S6-S8 Tables). 308 309

310

311 Table 1 Summary of characteristics of included studies and participants

Subgroups	Number of studies	Number of participants using DAT	Number of participants in SOC arm
All studies included	70	29,228	29,722
Publication type			
Full-text paper	54	14,801	14,027
Preprint	2	8,557	7,930
Abstract	13	5,301	7,230
Research letter	1	569	535
Study design			
RCT	38	12,422	10,453
Quasi-experimental	5	664	783
Cohort study*	27	16,142	18,486
DAT type			
SMS	18**	4,515	4,788**
VOT	17	1,628	2,502
MERM	18**	6,457	8,884**
Feature-phone	7	1,760	1,574
99DOTS	5	12,386	11,284
Other smartphone	5	1,377	1,774
Ingestible sensor	1	41	20
SMS+MERM	1**	1,064	1,104**
Country-income level			
Low	11	4,113	3,681
Lower-Middle	24	17,062	19,394
Upper-Middle	19	6,492	4,531
Upper-Middle and High	1	328	337
High	15	1,233	1,779
TB disease vs. infection			
TB disease	65	28,553	28,688
TB infection	4	628	987
Both	1	47	47
TB resistance for TB disease			
Drug-susceptible	40	22,797	24,172
Multi-drug resistant	2	151	211
Both drug-sensitive and drug-	2	138	79
resistant			
Unknown	21	5,467	4,226

312 313 * One study was a comparative cross-sectional study with retrospective data

** Liu et al 2015 included 3 DAT arms (SMS only, MERM only and SMS and MERM (combined) and 1 control arm

314

315

- *Risk of bias in included studies* 316
- 317

Performance bias was common in most RCTs, as it was not feasible to mask participants to 318 the interventions used. High risk of detection bias was also present in over 30% of the 319 studies, as outcome assessors were not blinded. All studies had either low or unclear risk of

320 selection bias. (S1 and S2 Figs). 321

322

More than 60% of the included observational studies showed high risk of bias related to 323 participant representativeness. Many studies required participants to be literate, have access to 324 a mobile phone, demonstrate digital literacy, and/or have a reliable internet connection in order 325 to participate. (S3 Fig, S9 and S10 Tables) 326

327

328 Short-term clinical outcomes in TB disease 329

A summary of findings for the effect of digital technologies on short-term clinical outcomes 330

in TB disease is provided in Figures 3 and 4 and S17 Table. 331

332

Treatment success. Overall, the use of digital technologies was associated with a small 333 increase in treatment success, with substantial heterogeneity across studies (OR = 1.18 [1.06, 334 1.33]; $I^2 = 66\%$, k = 46, [very low certainty evidence]). Video-observed therapy (OR 1.54 335 [1.09; 2.19]; $I^2 = 0\%$, k = 8, [low certainty evidence]) and smartphone-based technologies 336 (other) (OR 1.98 [1.07; 3.65]; $I^2 = 56\%$, k = 5, [low certainty evidence]) were each associated 337 with an increased likelihood of treatment success for persons with TB disease, as were digital 338 pillboxes) (OR 1.32 [1.00; 1.73]; $I^2 = 86\%$, k = 11, [low certainty evidence]) while other DAT 339 types were not. Further subgroup analysis suggested that VOT (OR = 1.55 [1.04; 2.31]; $I^2 =$ 340 341 0%, k = 5) were associated with greater treatment success in high-income countries, while smartphone-based technologies ($OR = 2.81 [1.11; 7.14]; I^2 = 33\%, k = 3$) were associated with 342 increased treatment success in upper-middle income countries. (S11 and S12 Tables, S4 Fig) 343 A supplementary meta-analysis showed that DATs used in high-income countries (OR = 1.55344 $[1.04; 2.31]; I^2 = 0\%, k = 5$ or upper-middle income countries (OR = 1.23 [1.02; 1.50]; I^2 = 1.00; 345 36%, k = 18) were associated with improvement in treatment success. (S16 Fig) 346

347

Loss to follow up. Similarly, DATs overall were associated with a significant decrease in the 348 proportion of patients lost to follow up, again with substantial heterogeneity (OR = 0.71 [0.53, 349 0.94; $I^2 = 80\%$, k = 36, [low certainty evidence]). Among the specific DATs, smartphone-based 350 interventions were associated with decreased likelihood of loss to follow up (OR = 0.31 [0.13; 351 0.77]; $I^2 = 36\%$, k = 5, [moderate certainty evidence]). (S13 Table, S5 Fig) In low-income 352 countries, loss to follow up was less frequent among persons using any DAT than among those 353 who received the local standard of care (S17 Fig). 354

355

362

356 Treatment failure and death. None of the digital technology interventions was associated with reductions in treatment failure. (S14 Table, S8 Fig). However, digital technologies overall 357 (OR= 1.19 [1.07, 1.32]; I²=0%, k=29, [low certainty evidence]) and medication sleeves with 358 phone calls (99DOTS) (OR = 1.25 [1.10, 1.42; $I^2 = 0\%$, k = 2, [low certainty evidence]) were 359 360 associated with a small increase in the likelihood of death. (S15 Table, S7 Fig) Importantly, clustering of participants could not be accounted for in this specific analysis. 361

Adverse events. The use of digital technologies was associated with an increase in the number 363 of persons reporting adverse events (OR = 1.53 [1.26; 1.86]; $I^2 = 0\%$, k = 8, [moderate certainty 364

medRxiv preprint doi: https://doi.org/10.1101/2024.01.31.24302115; this version posted February 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

evidence]). Subgroup analysis showed that VOT (OR = 1.79 [1.27; 2.52]; $I^2 = 0\%$, k = 4, 365 [moderate certainty evidence]) was associated with an increased frequency of adverse event 366 reporting. The combination of SMS and MERM (OR = 1.91 [1.27; 2.88]; $I^2 = N/A$, k = 1) also 367 significantly increased the number of adverse events reported. (S16 Table, S8 Fig). While in 368 most studies the number of adverse events corresponded to the number of persons who 369 reported any adverse event[19–22], in one study it referred specifically to persons for whom 370 adverse events led to longer TB treatment duration [23], and in another study it referred to 371 persons for whom adverse events led to treatment interruption.[24] Abdominal pain, nausea, 372 and vomiting were the most common adverse events reported. [19,20] 373

374

Cure. Seven studies reported on cure; none of the digital technology interventions was 375 associated with a difference in microbiologic cure among persons with TB disease. (S9 Fig) 376

377

Microbiologic conversion. Nine studies assessed microbiologic conversion of sputum smears 378 or cultures in persons with TB disease. Overall, there was no significant difference between 379 the DAT intervention and comparison groups. While eight studies addressed the proportion of 380 patients with microbiologic conversion in the DAT group compared to standard care, one study 381 [25] reported the mean time to culture conversion in the VOT group (47 days) vs. the standard 382 of care group (48 days). (S17 Table, S10 Fig) 383

Completion of intensive phase treatment. Three studies reported on completion of intensive 385 phase treatment for TB disease. None showed a significant association with DAT use. (S11 386 Fig) 387

388

384

Emergence of antibiotic resistance. Two studies reported on emergence of anti-TB antibiotic 389 390 resistance during treatment. Neither showed a significant association with DAT use. (S12 Fig) 391

- 392
- Publication bias 393
- 394

Publication bias was assessed using funnel plots for treatment success, loss to follow up, 395 treatment failure and death. Egger's test indicated asymmetry for treatment success (Egger's 396 $\beta_0 = 0.66$ [0.16 to 1.16]; $t_{(44)} = 2.58$; p = 0.01) suggesting potential publication bias reflected 397 by the relative paucity of larger studies with negative findings. (Fig 6) No publication bias was 398 399 detected for loss to follow-up, treatment failure or death. (S13-15 Figs) 400

- Sensitivity analysis 401
- 402

403 A sensitivity analysis was conducted after excluding studies reported as conference abstracts. Overall findings were mostly similar, except that there was no longer a significant association 404 between DAT use in general and loss to follow-up. Similarly, there was no longer a significant 405 association between the smartphone technology-based interventions and treatment success. 406

407

Short-term clinical outcomes in TB infection 408

409 410 Treatment completion. Four studies (1615 participants) addressed the use of DATs (2 SMS[26,27], 2 VOT[28,29]) in TB infection. Three studies were conducted in HIC and one 411 study included outpatient tuberculosis clinics in three HIC and one UMIC[27]. The definition 412 of treatment completion varied across the studies. Some studies involving weekly isoniazid-413 rifapentine treatment defined it as ingestion of 11 doses within 16 weeks [27,28], while another 414

medRxiv preprint doi: https://doi.org/10.1101/2024.01.31.24302115; this version posted February 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

study required ingestion of at least 80% or 90% of planned medication doses within specified time intervals, i.e. $\geq 80\%$ or 90% of prescribed INH doses within 12 months, or $\geq 80\%$ or 90% of prescribed rifampin doses within 6 months.[26] Overall, DAT use was associated with a significant increase in treatment completion. (OR = 1.77 [0.85, 3.66; I² = 77%, k = 4, [low certainty evidence]). (S18 Table, Fig 5). A subgroup analysis showed that only VOT was associated with improved treatment completion. (OR = 4.69 [2.08, 10.55; I² = 0%, k = 2)

Loss to follow up and adverse events. Results for loss to follow-up and adverse event reporting were inconsistent: one study suggested that VOT was associated with an increase in loss to follow-up[29], while another suggested that a two-way SMS-based intervention increased the number of adverse events reported.[26]

- 425
- 426 Long-term clinical outcomes
- 427

Two cohort studies [22,30]and one RCT [31]examined the frequency of recurrence after treatment for TB disease. Of these, only one cohort study suggested a lower rate of recurrence in the DAT group. The others found no difference.[30]

431

432 None of the included studies assessed death after treatment completion, or subsequent risk of433 TB disease among persons treated for TB infection.

- 434
- 435 *Adherence*

436
437 There was substantial methodological heterogeneity among studies reporting on adherence.
438 Key differences included the measurements used to assess adherence (S20 Fig), the interval

- 439 over which adherence was measured as well as the timing of the assessment. (S19 Table)
- 440

Of 19 studies examining SMS interventions, 13 (68%) reported adherence measures. In eight,
this reflected patient self-reports. Three studies assessed adherence in terms of (timely) clinic
attendance and one used pill-counts. When compared to simultaneous urine tests for isoniazid
metabolites self-reports over-reported medication ingestion. [32] Association of the SMS
interventions with treatment adherence was inconsistent. (Fig 7)

446

Of 17 studies reporting VOT interventions, 12 (71%) explicitly assessed treatment adherence,
based on the videos reviewed, and usually described by the ratio of observed to prescribed
doses. Some studies reported the proportion of doses, while others used categorical cut-offs
of 80% or 95% to define adherence. Most associated VOT use with improved adherence. (Fig
8)

452

Similarly, among 18 studies involving digital pillboxes, 13 (72%) assessed adherence of which
10 (55%) studies used the pillbox data (Fig 9). Some studies also used complementary
measures such as pill counts, self report by persons on treatment, or urine tests.[17,23,31] Most
suggested that the use of the pillboxes was associated with improved adherence.

457

Feature-phone based interventions were generally associated with improved adherence.[33,34] For interventions that used smartphone technology, results were inconsistent. While one study[35] suggested that the technology was associated with an improvement in treatment

adherence of persons with multi-drug resistant TB, the two other studies found conflicting 461 results among persons with drug-sensitive TB. [36,37] 462

463

465

Patient-reported outcomes 464

Satisfaction. Satisfaction of people with TB with their care was assessed in 2 SMS 466 studies.[38,39] One study assessed satisfaction at the end of the sixth month on treatment with 467 a Likert scale.[38] In this study, satisfaction appeared high and similar between SMS and 468 standard of care groups based on two general questions. Another SMS study [39] assessed 469 470 satisfaction with the provider-patient relationship using a more detailed 7-item questionnaire; satisfaction was significantly higher in the intervention group than in the control group. (S20 471 Table) 472

- 473
- 474 Three VOT studies [19,20,40] used surveys to measure satisfaction among persons with TB; all reported greater satisfaction among participants in the VOT groups. 475
- 476

477 Only one study [18] reported satisfaction of persons with TB with the digital pillbox, using the Treatment Satisfaction Ouestionnaire for Medication (TSOM). It includes 14 questions across 478 four domains: Effectiveness, Convenience, Side Effects, and Global Satisfaction. Satisfaction 479 480 was significantly greater in the DAT group than in the control group in all domains assessed. (Table 17) 481

482

Health related quality of life. Four studies (one SMS, one VOT, and two digital pillbox 483 studies) assessed health related quality of life (HRQOL) in persons with TB disease 484 [16,19,34,41] using DATs, while one SMS study evaluated HRQOL in persons with TB 485 486 infection [26]. All five studies used versions of the EuroQol questionnaires and found no differences between participants in the DAT and standard care groups. 487 488

Stigma. One study measured TB-related stigma from the patient and family perspectives using 489 the Van Rie stigma scale. [34] It did not identify any significant difference in stigma reported 490 by persons with TB and their families supported by a feature-phone intervention vs. those who 491 received standard care. 492

- 493
- Special populations 494

495 496 Other prespecified stratified analyses involving children, persons living with HIV, those with drug resistant TB disease, and those with extrapulmonary TB disease were not conducted as 497 498 no sufficiently homogeneous studies were found for each subgroup.

- 499
- Discussion 500
- 501

Our systematic review aimed to assess the impact of digital technologies on clinical outcomes, 502 adherence, and patient-reported outcomes among persons treated for TB disease and infection. 503 We included randomized and quasi-experimental studies, as well as cohort studies, from 504 diverse country settings. 505

506

Some digital technologies, notably those involving video observation or other smartphone 507 technologies, were associated with improved treatment success and reduced losses to follow-508 509 up. They may also enhance adverse event reporting. These findings are concordant with previous reviews [5,8,42,43]. Similarly, VOT was associated with improved adherence to 510

expected dosing. However, VOT and smartphone intervention studies were overwhelmingly 511 conducted in high-income and upper-middle-income countries. Hence the generalizability of 512 these findings to low-income and lower-middle-income country settings, which experience 513 most of the world's TB incidence, may be limited. Low-income and lower-middle-income 514 countries may face greater challenges in mobile coverage and accessibility, and in health 515 system capacity to implement DATs. 516

517

Indeed, SMS-based interventions and medication sleeves with phone calls (99DOTS), which 518 were largely implemented in LMIC settings, were not consistently associated with improved 519 adherence or clinical outcomes. In fact, 99DOTs may have been associated with an increased 520 frequency of death, raising the possibility of gaps in patient supervision and support.[44] 521 However, this result should be interpreted with caution as the effect of confounders was not 522 523 adjusted for. Clustering was also not considered in one of the 99DOTS studies. It is also 524 possible that deaths appeared more frequent if there were fewer losses to follow-up, as the latter are a key competing risk. 525

526

527 Digital pillbox-based interventions, which were also mostly implemented in LMIC settings, also had variable associations with clinical outcomes. While digital pillboxes were associated 528 with increased medication adherence, these findings were often reported from studies that 529 530 compared adherence data from a "silent" pillbox (i.e., without reminders) in the control arm to a pillbox that provided audiovisual reminders in the intervention arm. This approach may 531 increase risk of detection bias, as people receiving audiovisual reminders may be more inclined 532 to keep medication blister packs within the device, thereby increasing engagement with the 533 DAT. Earlier studies and a forthcoming systematic review have highlighted limits to the 534 535 accuracy of dose reports with 99DOTS and reveal considerable variability in the accuracy of 536 dose reports from digital pillboxes. [45–47]

537

The increased reporting of adverse events with the VOT and smartphone platforms is likely a 538 positive consequence of more consistent opportunities for contact with providers. Reporting 539 of more adverse events by persons treated using VOT may indicate that more medication is 540 taken. Reporting of adverse events is important to manage potential complications, and to 541 address concerns that may affect adherence to treatment.[20] 542

543

Unfortunately, no study evaluated deaths post-treatment, and most did not report on recurrent 544 TB disease or emergence of drug resistance at any time. 545

546

Importantly, many of the VOT and digital pillbox studies also included co-interventions to 547 enhance patient support, beyond dose monitoring. Examples include medication 548 549 reminders, [19,22,25,28,40,48–51] encouraging adverse event reporting [19,20,22,24,40,48] and/or escalation via SMS, phone calls, or home visits if expected video observation was 550 missed. Some VOT interventions were coupled with motivational SMS, reimbursement of 551 552 mobile data costs, payment for visit attendance, or nutritional allowances. [19,20,29,48,52] Similarly, for interventions that involved smartphone technologies, most studies described 553 various combinations of associated measures e.g., medication reminders, adverse event 554 555 reporting, instant messaging, chat groups with providers and/or other patients. [37,53,54] 556

The diversity of comparison strategies reported as the "standard of care" further complicates 557 558 interpretation and inference. While most studies indicated daily provider-administered DOT (facility-or field-based) as the comparator, others used family DOT or self-administered 559 treatment, a combination of approaches, or simply did not specify. 560

561

Strengths of this review include a comprehensive search, which ultimately yielded a large 562 number of included studies (n = 70), with many participants (n = 58,797) in diverse settings, 563 permitting more detailed, stratified analyses. We also assessed the potential association of 564 DATs with a variety of outcomes. 565

566

However, our review has several limitations. Most studies reporting VOT or other smartphone 567 technology-based interventions were conducted in high- or upper-middle income countries. 568 This substantially limits generalizability of findings regarding these two technologies to lower-569 income country settings where TB burden is highest, yet where these technologies and the 570 necessary technical and human resource infrastructure may be least accessible. Notably, 571 however, our review does report robust findings from studies in LMICs: the DAT types 572 implemented in these settings (e.g., SMS, 99DOTS, digital pillboxes) had variable or non-573 574 significant impacts on treatment outcomes, which has important policy implications.

575

576 There was also substantial heterogeneity in study findings, which is not surprising given the 577 diversity of study settings, methodologies, technologies and comparators considered. This 578 limited our ability to formally pool and meta-analyze data, and made some quantitative findings less robust. 579

580

581 We could not assess treatment success and treatment completion as separate outcomes: some studies used the two terms interchangeably. While the treatment success category includes 582 583 both persons with microbiologic cure and those who completed treatment without known 584 microbiologic failure, most studies did not report microbiologic cure.

585

In this meta-analysis, we estimated odds ratios for some short-term clinical outcomes from 586 crude event numbers reported in cluster randomized trials, as no adjusted estimates were 587 provided. This may have resulted in artificially narrow confidence intervals when clustering 588 was ignored. 589

590

We focused on evidence from RCTs, quasi-experimental studies and cohort studies. For this 591 reason, cross-sectional studies which assessed patient-reported outcomes-often without a 592 comparison group—were excluded. More generally, there was very limited evidence around 593 the use of DATs in persons with drug-resistant TB, in children, or in persons living with HIV. 594

595

Conclusion 596

597

While the evidence base remains incomplete, and generalizability of studies often limited, this 598 systematic review nonetheless synthesizes relevant information and identifies further evidence 599 gaps. It provides insights into how some DATs can be successfully used to support curative 600 and preventive TB treatment. VOT and smartphone interventions were associated with 601 increased treatment success in high-income settings and should strongly be considered together 602 with digital pillboxes as alternatives to DOT when appropriate. SMS, 99DOTS, and other 603 feature-phone based interventions did not improve treatment success or had highly variable 604 findings, with most studies conducted in LMIC settings. This finding has important policy 605 implications and raises questions regarding investments in the DATs as currently designed and 606 implemented. With the rapid growth of technology and mobile usage worldwide, programs, 607

patients, and providers will increasingly look to digital technologies for support. The 608 combination and fine-tuning of different support interventions, with a more personalized 609 delivery approach, is promising. However, there remain substantial knowledge gaps with 610 respect to key populations and to longer-term health outcomes. 611 Beyond issues of generalizability to settings and populations which bear the highest TB burdens, there also 612 remain important questions related to implementation and logistics. Further research is urgently 613 needed to rethink approaches to DATs-and to inform non-DAT-based approaches to 614 improving TB treatment outcomes in LMICs. 615

References

- 1. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. 2016. doi:10.1371/journal.pmed.1002152
- 2. Global tuberculosis report 2023. 2023 [cited 17 Dec 2023]. Available: https://iris.who.int/.
- World Health Organization. Global Tuberculosis Control Surveillance, Planning, Financing, 2004 : WHO report 2004. World Health Organization; 2004.
- 4. Subbaraman R, De Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities Analysis. BMJ Glob Health. 2018;3: 1018. doi:10.1136/bmjgh-2018-001018
- Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51. doi:10.1183/13993003.01596-2017
- 6. Wong YJ, Ng KY, Lee SWH. Digital health use in latent tuberculosis infection care: A systematic review. Int J Med Inform. 2022;159: 104687. doi:10.1016/J.IJMEDINF.2022.104687
- Truong CB, Tanni KA, Qian J. Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. Am J Prev Med. 2022;62: 450–458. doi:10.1016/J.AMEPRE.2021.10.013
- Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. J Med Internet Res. 2022;24. doi:10.2196/33062
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021;18: e1003583. doi:10.1371/JOURNAL.PMED.1003583
- 10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7: 177–188. doi:10.1016/0197-2456(86)90046-2
- 11. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. JSS Journal of Statistical Software. 2010. Available: http://www.jstatsoft.org/
- 12. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health. 2019;22: 153–160. doi:10.1136/ebmental-2019-300117
- New World Bank country classifications by income level: 2022-2023. [cited 12 Nov 2023]. Available: https://blogs.worldbank.org/opendata/new-world-bank-country-classificationsincome-level-2022-2023
- 14. Egger M, Smith GD, Schneider M, Minder C. Papers Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997.
- 15. Hasselblad V, Hedges L V. Meta-Analysis of Screening and Diagnostic Tests. Psychol Bull. 1995;117: 167–178. doi:10.1037/0033-2909.117.1.167

- 16. Manyazewal T, Woldeamanuel Y, Fekadu A, Holland DP, Marconi VC. Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients with Tuberculosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022;5: E2230509. doi:10.1001/jamanetworkopen.2022.30509
- Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Marconi VC. Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial. BMC Med. 2022;20. doi:10.1186/s12916-022-02521y
- Manyazewal T, Woldeamanuel Y, Getinet T, Hoover A, Bobosha K, Fuad O, et al. Patientreported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial. EClinicalMedicine. 2023;56. doi:10.1016/j.eclinm.2022.101820
- 19. Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analystblinded, randomised, controlled superiority trial. The Lancet. 2019;393: 1216–1224. doi:10.1016/S0140-6736(18)32993-3
- 20. Ravenscroft L, Kettle S, Persian R, Ruda S, Severin L, Doltu S, et al. Video-observed therapy and medication adherence for tuberculosis patients: Randomised controlled trial in Moldova. European Respiratory Journal. 2020;56. doi:10.1183/13993003.00493-2020
- 21. Dewi FST, Sudiya S, Supriyati Supriyati, Utarini A. Preparing Short Message Service Reminders to Improve Treatment Adherence among Tuberculosis Patients in Sleman District, Indonesia. Indian J Community Med. 2019;44: 81–87. doi:10.4103/IJCM.IJCM_207_18
- 22. Guo X, Yang Y, Takiff HE, Zhu M, Ma J, Zhong T, et al. A comprehensive app that improves tuberculosis treatment management through video-observed therapy: Usability study. JMIR Mhealth Uhealth. 2020;8. doi:10.2196/17658
- 23. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med. 2015;12. doi:10.1371/journal.pmed.1001876
- 24. Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. International Journal of Tuberculosis and Lung Disease. 2016;20: 588–593. doi:10.5588/ijtld.15.0738
- Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. International Journal of Tuberculosis and Lung Disease. 2021;25: 655–661. doi:10.5588/ijtld.21.0170
- 26. Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, et al. The effect of text messaging on latent tuberculosis treatment adherence: A randomised controlled trial. European Respiratory Journal. 2018;51. doi:10.1183/13993003.01488-2017
- 27. Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection. Ann Intern Med. 2017;167: 689–697. doi:10.7326/M17-1150

- 28. Lam CK, Pilote KMG, Haque A, Burzynski J, Chuck C, Macaraig M. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: An implementation study. J Med Internet Res. 2018;20. doi:10.2196/jmir.9825
- 29. Chen SH, Wang I, Hsu HL, Huang CC, Liu YJ, Putri DU, et al. Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection. J Infect Public Health. 2020;13: 1354–1359. doi:10.1016/j.jiph.2020.03.013
- 30. Doltu S, Ciobanu A, Sereda Y, Persian R, Ravenscroft L, Kasyan L, et al. Short and long-term outcomes of video observed treatment in tuberculosis patients, the Republic of Moldova. J Infect Dev Ctries. 2021;15: 17S-24S. doi:10.3855/jidc.14601
- 31. Liu X, Thompson J, Dong H, Sweeney S, Li X, Yuan Y, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health. 2023;11: e693–e703. doi:10.1016/S2214-109X(23)00068-2
- 32. Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: A randomized controlled trial. PLoS One. 2016;11. doi:10.1371/journal.pone.0162944
- Santra S, Garg S, Basu S, Sharma N, Singh MM, Khanna A. The effect of a mhealth intervention on anti-tuberculosis medication adherence in Delhi, India: A quasi-experimental study. Indian J Public Health. 2021;65: 34–38. doi:10.4103/ijph.IJPH_879_20
- Khachadourian V, Truzyan N, Harutyunyan A, Petrosyan V, Davtyan H, Davtyan K, et al.
 People-centred care versus clinic-based DOT for continuation phase TB treatment in Armenia: A cluster randomized trial. BMC Pulm Med. 2020;20. doi:10.1186/s12890-020-1141-y
- 35. Zhou X, Zuo T, Zhao X, Cheng T, Zhao J. Effect of mobile app-based nursing health education on patients with pulmonary multidrug-resistant tuberculosis. 49th Union World Conference on Lung Health. The Hague, The Netherlands: International Union Against Tuberculosis and Lung Disease (The Union); 2018. p. S288.
- 36. Haslinda Noor I. JMH. EFFECTIVENESS OF HEALTH EDUCATION MODULE DELIVERED THROUGH WHATSAPP TO ENHANCE TREATMENT ADHERENCE AND SUCCESSFUL OUTCOME OF TUBERCULOSIS IN SEREMBAN DISTRICT, NEGERI SEMBILAN, MALAYSIA. International Journal of Public Health and Clinical Sciences. 2019;6. doi:10.32827/ijphcs.6.4.145
- Zhang M, Wang G, Najmi H, Yaqoob A, Li T, Xia Y, et al. OPEN ACCESS EDITED BY Digitizing tuberculosis treatment monitoring in Wuhan city, China, Impact on medication adherence. 2023.
- Bediang G, Stoll B, Elia N, Abena JL, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): A randomised controlled trial. BMC Public Health. 2018;18. doi:10.1186/s12889-018-5502-x
- 39. Gashu KD, Gelaye KA, Lester R, Tilahun B. Effect of a phone reminder system on patientcentered tuberculosis treatment adherence among adults in northwest ethiopia: A randomised controlled trial. BMJ Health Care Inform. 2021;28. doi:10.1136/bmjhci-2020-100268

- 40. Guo P, Qiao W, Sun Y, Liu F, Wang C. Telemedicine technologies and tuberculosis management: A randomized controlled trial. Telemedicine and e-Health. 2020;26: 1150– 1156. doi:10.1089/tmj.2019.0190
- 41. Saha S, Saxena D, Raval D, Halkarni N, Doshi R, Joshi M, et al. Tuberculosis Monitoring Encouragement Adherence Drive (TMEAD): Toward improving the adherence of the patients with drug-sensitive tuberculosis in Nashik, Maharashtra. Front Public Health. 2022;10. doi:10.3389/FPUBH.2022.1021427/FULL
- 42. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15. doi:10.1371/journal.pmed.1002595
- 43. Oeser C, Rangaka MX, Abubakar I. Digital approaches to reducing TB treatment loss to followup. Int J Tuberc Lung Dis. 2023;27: 432–437. doi:10.5588/IJTLD.23.0027
- 44. Thekkur P, Kumar ANV, Chinnakali P, Selvaraju S, Bairy R, Singh AR, et al. Outcomes and implementation challenges of using daily treatment regimens with an innovative adherence support tool among HIV-infected tuberculosis patients in Karnataka, India: a mixed-methods study. Glob Health Action. 2019;12. doi:10.1080/16549716.2019.1568826
- 45. Subbaraman R, Thomas BE, Kumar JV, Lubeck-Schricker M, Khandewale A, Thies W, et al. Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India. Open Forum Infect Dis. 2021;8. doi:10.1093/OFID/OFAB532
- 46. Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, et al. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. [cited 14 Dec 2023]. doi:10.1186/s12879-018-3080-2
- Van Den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89: 632–639. doi:10.2471/BLT.11.086462
- Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, et al. Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA. Emerg Infect Dis. 2018;24: 1806–1815. doi:10.3201/eid2410.180459
- 49. Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era of COVID-19. BMC Infect Dis. 2022;22. doi:10.1186/s12879-022-07787-4
- 50. Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic Adoption and Implementation of Video-Observed Therapy in Minnesota: Prospective Observational Cohort Study. JMIR Form Res. 2022;6. doi:10.2196/38247
- 51. Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multi-centre randomised controlled trial. 2023. Available: https://ssrn.com/abstract=4387313

- 52. Burzynski J, Mangan JM, Lam CK, Macaraig M, Salerno MM, Decastro BR, et al. In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial. JAMA Netw Open. 2022;5. doi:10.1001/jamanetworkopen.2021.44210
- 53. Iribarren SJ, Milligan H, Chirico C, Goodwin K, Schnall R, Telles H, et al. Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. 2022. doi:10.1016/j
- 54. Zhdanova SN, Ogarkov OB, Heysell SK. Mobile health intervention for outpatient treatment of tuberculosis and HIV infection. Acta Biomed Sci. 2020;5: 46–53. doi:10.29413/ABS.2020-5.3.7




Fig 1 The PRISMA flow diagram explaining the flow of information through the different phases of the systematic review. *One UNION conference abstract was published in March 2023 as a Lancet preprint that was not caught in the search via Europe PMC database. The preprint was included instead.




Fig 2 Distribution of DATs by country-income-level. MERM digital pillboxes, **SMS+ MERM** a combination of SMSbased intervention and digital pillboxes, **VOT** video observed therapy. One study included 3 different DAT intervention arms, and one was conducted in several upper-middle and high-income countries.

DAT-group	Number of studies	DATN	SOC N	OR [95% CI]	12 (%)	Odds Ratio
Outcome = Trea	tment success					44
SMS	9	3341	3583	1.18 [0.92; 1.53]	48.2	
VOT	8	695	1047	1.54 [1.09; 2.19]	0	
MERM	11	4566	7037	1.32 [1.00; 1.73]	71.4	
Feature-phone	7	1650	1464	1.01 [0.53; 1.94]	86	· · · · · · · · · · · · · · · · · · ·
99DOTS	5	12386	11284	0.92 [0.77; 1.10]	57.7	
Other	5	1377	1774	1.98 [1.07; 3.65]	56.1	
SMS+MERM	1	1064	1104	1.00 [0.45; 2.21]		
Outcome = Adve	erse event reporting					
SMS	2	1068	1164	1.23 [0.84; 1.80]	0	
VOT	4	493	694	1.79 [1.27; 2.52]	0	
MERM	1	997	1104	1.22 [0.78; 1.91]		
SMS+MERM	1	1064	1104	1.91 [1.27; 2.88]		
Outcome = Cure						
SMS	2	289	296	1.23 [0.85; 1.78]	0	
Feature-phone	1	227	209	1.37 [0.78; 2.39]	· ·	
MERM	1	124	126	0.54 [0.27; 1.10]		
99DOTS	2	9192	8683	0.51 [0.16; 1.64]	98.8	
Other	1	1145	1576	0.86 [0.72; 1.03]		-
Outcome = Micro	obiological conversion					
SMS	1	283	291	1.16 [0.78; 1.73]		
VOT	1	235	158	1.91 [0.92; 3.96]		
MERM	4	1521	1675	1.17 [0.65; 2.09]	63.9	
Other	1	112	112	5.06 [2.57; 9.96]		— —
Outcome = Com	pletion of intensive phase	e				
SMS	1	283	291	0.90 [0.63; 1.28]		
99DOTS	2	2885	2469	0.95 [0.75; 1.20]	0	
						0.2 0.5 1 2
						0.2 0.3 1 2

Fig 3 Pooled estimates for favorable short-term clinical outcomes in TB disease stratified by type of DAT

DAT-group	Number of studies	DATN	SOC N	OR [95% CI]	l2 (%)	Odds Ratio
Outcome = Loss	s to follow up					
SMS	9	3181	3428	0.85 [0.57; 1.25]	64.7	
VOT	4	419	716	1.16 [0.46; 2.95]	0	
MERM	8	3259	6019	0.40 [0.13; 1.25]	88.7	
Feature-phone	5	1228	1103	1.14 [0.31; 4.22]	90	
99DOTS	4	12077	11152	0.99 [0.68; 1.45]	80.3	+
Other	5	1377	1774	0.31 [0.13; 0.77]	35.8	
SMS+MERM	1	1064	1104	0.90 [0.38; 2.12]		
Dutcome = Trea	tment failure					
SMS	6	2810	3022	1.09 [0.62; 1.91]	12.2	
VOT	1	203	202	0.79 [0.21; 2.99]		
MERM	6	2959	5353	1.00 [0.97; 1.02]	0	
eature-phone	4	1018	855	0.55 [0.11; 2.73]	82.6	
99DOTS	2	9192	8683	0.90 [0.24; 3.46]	27.9	
Other	3	1312	1743	0.77 [0.38; 1.57]	0	
SMS+MERM	1	1064	1104	1.07 [0.22; 5.34]		
Dutcome = Deat	th					
SMS	6	2873	3090	1.19 [0.78; 1.83]	30.9	
VOT	4	470	714	0.79 [0.22; 2.84]	0	
MERM	8	3066	5460	0.85 [0.57; 1.25]	5.4	
eature-phone	4	1018	855	1.05 [0.37; 2.95]	29.9	
9DOTS	2	9192	8683	1.25 [1.10; 1.42]	0	
Other	4	1333	1764	1.29 [0.79; 2.11]	0	
SMS+MERM	1	1064	1104	1.27 [0.42; 3.79]		
Dutcome = Eme	rgence of anti-TB drug re	sistance				
SMS	1	283	291	4.16 [0.46; 37.42]		
Other	1	1145	1576	0.26 [0.06; 1.23]		

0.1 0.5 1 2 10

Fig 4 Pooled estimates for unfavorable short-term clinical outcomes in TB disease stratified by type of DAT

Author	DATN	SOC N	OR [95% CI]	Weight	Odds Ratio
DAT = SMS					
Belknap et al	328	337	1.13 [0.80; 1.62]	34.6%	-
Johnston et al	170	188	0.88 [0.52; 1.49]	31.6%	
Random effects mode	el		1.05 [0.78; 1.40]	66.2%	+
Heterogeneity: $I^2 = 0\%$, τ	$r^2 = 0, p = 0$	0.44			
DAT = VOT					
Chen et al	80	160	11.29 [1.49; 85.69]	9.6%	
Lam et al	50	302	3.97 [1.64; 9.61]	24.2%	
Random effects mode	el		4.69 [2.08; 10.55]	33.8%	
Heterogeneity: $I^2 = 0\%$, τ	$p^2 = 0, p = 0$	0.35	•		
Random effects mod			1.77 [0.85; 3.66]	100.0%	
Heterogeneity: $I^2 = 77\%$, Test for subgroup different					0.1 0.51 2 10

Fig 5 Forest plot showing treatment completion in DAT groups compared to standard of care among persons with TB infection




Fig 6 Funnel plot of included studies for the assessment of publication bias using Egger's test. It shows studies comparing treatment success in patients using DATs versus standard care. Each point represents an individual study. Varying levels of statistical significance of the studies are indicated by the shading; the unshaded region in the middle corresponds to p-values greater than 0.10, the dark gray-shaded region corresponds to p-values between 0.05 and 0.10, the medium gray-shaded region corresponds to p-values between 0.01 and 0.05, and the region outside of the funnel corresponds to p-values below 0.01.

Author	Duration	Measure of assessment	N DAT	N control	OR [95% CI]	Odds Ratio
Unit_of_anlaysis = Patie	nt				And a second	
Bediang et al	1 month	0 to 100% Visual analog scale	137	142	1.22 [0.80; 1.87]	
Fang et al	2 months	A guestionnaire to assess suboptimal adherence (cut-off 100%)	160	190	3.66 [2.24; 5.97]	
Gashu et al	4 months	11-item Adherence to Refill and Medication Scale (ARMS)	152	154	1.63 [1.09; 2.44]	
Hirsch-Moverman et al	1 month*	Follow up interviews about drug intake (cut-off 100%)	183	166	2.10 [1.15; 3.83]	
Kibu et al (one-way SMS)	not clear	Composite score derived from VAS and CASE adherence index ##	28	28	0.46 [0.17; 1.24]	
Kibu et al (two-way SMS)	not clear	Composite score derived from VAS and CASE adherence index ##	28	28	0.40 [0.15; 1.06]	
Kumboyono	not clear	Observation sheet with three items ###	45	45	3.50 [0.88: 13.92]	
Louwagie et al	4 days	Modified version of ACTG Adherence Questionnaire (cut-off point 95%) #	283	291	1.12 [0.33; 3.86]	
					favour	0.1 0.5 1 2 10 rs standard care favours DA

Fig 7 Forest plot showing self-reported adherence to TB treatment in SMS groups versus standard of care. * Adherence was assessed monthly in follow-up visits, # ACTG AIDS Clinical Trials Group. An adherence index was calculated using the 4-day recall formula [doses taken/ doses prescribed], ## VAS Visual Analogue Scale; (CASE) Center for Adherence Support Evaluation, ### observation sheet including three items: the number of drugs consumed; the type of drugs; the time of drug consumption. Patients who satisfy all three subjects are considered adherent

Author	Duration	Definition	N DAT	N control	OR [95% CI]	Odds Ratio
Unit_of_analysis = [Dose			C D S C		
Bachina et al	6 months	Doses observed/ doses prescribed	23	26	27.14 [7.98; 92.33]	
Burzynski et al	1 month	Doses observed/ doses prescribed	113	103	1.24 [1.06; 1.44]	-
Chen et al	9 months	Doses observed/ doses prescribed	80	160	2.26 [1.39; 3.69]	
Garfein et al	6 months	Doses observed/ doses prescribed	272	159	8.35 [5.70; 12.22]	-
Lippincott	not clear	Doses observed/ doses prescribed*	30	22	4.27 [1.12; 16.24]	
Perry et al	>2 months	Doses observed/ doses prescribed	94	69	3.69 [2.18; 6.25]	
Siddiqui et al	not clear	Doses observed/ doses prescribed	47	47	0.34 [0.26; 0.45]	
Unit of analysis = F	Patient					
Doltu et al	3 months	Doses observed/ doses prescribed (cut-off 80%)	83	478	41.02 [16.53; 101.80]	
Guo et al (a)	6 months	Doses observed/ doses prescribed (cut-off 95%)**	235	158	36.70 [16.44; 81.89]	
Ravenscroft et al	6 months	Doses observed/ doses prescribed (cut-off 80%)	85	93	12.80 [10.57; 15.49]	2 -
	2 months	Doses observed/ doses prescribed (cut-off 80%)	112	114	5.48 [3.10; 9.68]	

Fig 8 Forest plot showing comparing dose observation in VOT groups versus standard of care. * Prescribed doses that could not be confirmed as ingested were recorded to be 'missed' or 'self-administered' based on chart documentation, ** The numerator includes either directly observed or video-observed doses, excluding those obtained by self-report. The denominator includes the self-administered medications; it does not include periods when the treatment was suspended based on medical advice because of side effects.

Author	Duration	Definition	N DAT	N control	OR [95% CI]	Odds Ratio
Unit_of_analysis = Patie	nt					
Acosta et al	4 months	Doses taken/ doses expected (cut-off point 100%)	53	53	1.36 [0.56; 3.35]	
Charalambous et al	168 days	Doses taken/ doses expected (cut-off point 80%)	1306	1278	2.50 [1.86; 3.35]	
iu et al 2015	1 month*	Patient-months with at least 80% doses taken	997	1104	2.86 [2.05; 4.01]	
Liu et al 2023	6 months	Doses taken per person per doses expected	1298	1388	2.18 [1.84; 2.59]	
Manyazewal et al	15 days**	Geometric mean of doses taken #	57	57	1.00 [0.99; 1.01]	
Moulding & Caymittes	9 months	Doses taken/ doses expected (cut-off 80%)	64	59	1.64 [0.59; 4.57]	
Park et al	1 month***	Monthly drug adherence rate for TB medication	206	141	1.27 [0.86; 1.87]	
Ratchakit-Nedsuwan et al	6 months	Doses taken/ doses expected (cut-off 80%)	50	50	3.16 [0.31; 31.78]	
/elen et al	1 month****	Patient-months with at least 80% doses taken	124	126	2.20 [1.47; 3.29]	
Vei et al	1 month*	Patient-months with at least 80% doses taken	142	134	2.94 [2.18; 3.97]	
						0.1 0.5 1 2 10
					favours	standard care favours DA

Fig 9 Forest plot showing adherence to TB medication dosing from digital pillbox data in digital pillbox group versus standard of care. * The study provided the percentage of patient-months on TB treatment where at least 20% of doses were missed. Adherence was measured for 6 months, ** Four 15-day appointments (intensive phase), *** The study provided the mean monthly drug adherence. Adherence was measured monthly for 6 months, *** Adherence was measured monthly for 6 months, # individual-level % adherence averaged over the 2-month intensive phase measured